Australian equity capital raisings during COVID: A record breaking year

The explosion of COVID-19 cases in early 2020 saw economic uncertainty hit the markets. Volatility spiked and equity markets fell sharply – the S&P/ASX200 almost halved in value over the 22 trading days from February 21st*.

In Australia reporting season had just finished, yet we quickly saw earnings guidance retracted and announced dividends cancelled before their pay date (to our knowledge no company had ever cancelled a dividend after announcement before).

It quickly became apparent that many companies would likely require additional cash and quickly. In response, on March 31st, ASIC and the ASX announced a ‘temporary emergency capital raising relief’, unprecedented regulatory changes that allowed capital to be raised rapidly and in larger amounts, (most notably was an increase from 15% to 25% for share placements). At the same time, ASIC guided (but did not demand) financial institutions to withdraw or defer dividend payments, in an attempt to retain capital to support the upcoming economic downturn.

Almost immediately there was a large jump in capital raisings – in April alone 26 companies in the S&P/ASX300 issued new stock. By the end of 2020, 104 of these companies had undertaken raisings - the most number of companies that had ever raised equity in single year - totalling almost $40 billion¹.

Capital raisings in 2020 by month (S&P/ASX300 companies)

Source: Realindex, Factset. Data as at 30^th June 2021.

Large firms which raised capital during this period included²:

• Cochlear, the first company to raise in Covid, it shored up its balance sheet with an $800m placement in late March 2020. The new shares were priced at $140 (a 17% discount to the last price of $168) and the market responded favourably with shares trading above $180 afterwards.
• Ramsay Healthcare raised $1.4b via a placement in April to provide essential cash flow after elective surgeries were suspended in Australia whilst in the UK and France (where it also owns hospitals) the healthcare systems were severely stressed. Issued at a 13% discount, shares resumed trading above the issue price of $56.00 but not above the pre raising close price of $64.29.
• Shopping Centre owner Vicinity Centres also felt the front line of the virus impacts as its tenants were forced close in response to coronavirus restrictions. By June they were forced to raise $1.4b (a 23% increase in issued capital) to repair the balance sheet. Vicinity shares struggled to maintain the $1.48 issue price until the broad market recovery in November.
   

Whilst raisings occurred across all sectors, they were overrepresented in Consumer Discretionary and Real Estate as many companies in these sectors such as retailers, hotels, educators and shopping centres (as mentioned above with Vicinity) faced even higher uncertainty of earnings and cash flows.

2020 raisings by sector

Source: Realindex, Factset. Data as at 30^th June 2021.

However without doubt the hardest hit were travel-related firms including Flight Centre, Qantas and Sydney Airport who all raised capital out of necessity as domestic and international travel dropped to near zero.

Covid raisings by travel related companies

Source: Realindex, Factset. Data as at 30^th June 2021.

While corporates needed to raise capital, investors who supported these raisings need to have some belief or likelihood that their investments would perform well.

Next, we look at whether investors were indeed successful in participating.

Participating in raisings during 2020 has been profitable, with 75% of these S&P/ASX300 companies outperforming the market over the following month (with an average return excess to the S&P/ASX200 of 13%). However, as the chart following shows, much of this outperformance occurs in the first few days.

Following this initial spike in performance – having purchased the stock at the issue price - returns have either drifted downwards (median) or stayed flat (mean) for at least the 50 days following the raising. (Note that mean and median here are equally weighted.)

Excess return around announcement (against issue price)

Source: Realindex, Factset. Data as at 30^th June 2021.

As noted however this performance is measured using the issue price – the discounted price at which the new shares could be purchased. Equity raisings are usually conducted at a discount to last price or volume-weighted average price (VWAP), as an enticement to participate. In 2020, the average discount to the last traded price was larger than normal, to increase the incentive, at around 10%.

If we reset the chart above to use last price prior to the raising rather than discounted capital raising price, the performance is more grim - two thirds  of these stocks underperform with an average excess return of -1.3% (see chart below).

Excess return around announcement (against last traded price)

Source: Realindex, Factset. Data as at 30^th June 2021.

This provides an interesting demonstration of the two sides of equity capital raisings:

• Participate in the deal and on average you can earn a profit in the short term
• Equity raisings usually underperform longer term.
   

So the investment rule should be to take up profitable capital raisings at the issue time, but be underweight firms that raise capital, on average. This result also appears to depend on the market conditions at the time, as we will see below.

Whilst 2020 was a record year for the number of companies undertaking a raising, the total amount raised was far less than in the global financial crisis (GFC) peak of 2009. This is because few very large companies raised capital in 2020 whilst they dominated in the GFC (in 2020 over 90% of raisings were made by companies outside of the S&P/ASX 50 leaders). For example in 2008-09 the 4 big banks all raised - CBA and ANZ twice. In 2020 only NAB raised funds and this was done concurrent to paying a dividend.  

Number of issues and total issue value

Source: Realindex, Macquarie Research. Data as at 30^th June 2021.

As the chart below shows, returns post raising in 2020 were far greater than is historically seen (with the exception of 2009), this stronger performance in the two crisis periods reflects the market's confidence in both the firm’s ability to successfully complete the deal and a reduction in the company’s uncertainty over the short term.

On the other hand, in ‘normal’ market conditions (for example, from 2013 to 2017), while the post raising returns are positive, they are countered by more opportunistic raisings. For example, a company might issue new shares when their share price is very high or raise funds for nonspecific purposes (such as ‘future growth opportunities’). The market tends to less favourably reward these type of deals, and these types of raisings tend to underperform in the longer term.

Average excess return 1 month post raising (relative to the offer price)

Source: Realindex, Macquarie Research. Data as at 30^th June 2021.

Longer term performance of raisings

The chart following shows that over the longer term, COVID raisings have performed better than other time periods. One, 6 and 12 month returns are better for the COVID than for the other periods shown³.

This performance in 2020 is exaggerated by the dominance of small companies raising capital. Small cap stocks significantly outperformed during this time (the Small Ordinaries returned 9.2% in 2020 versus 1.4% for the S&P/ASX200)⁴. If these smaller deals were measured against the Small Cap benchmark (rather than the S&P/ASX200) they would show similar outperformance more in line with history.

Longer term excess performance

Source: Realindex, Macquarie Research. Data as at 30^th June 2021.

The chart above also suggests better performance outcomes in the longer term in more normal markets (given the stronger long term performance of the post GFC period versus the GFC).

This is likely to be due to various deal characteristics that are more prevalent in non-crisis markets. For example, more raisings may be undertaken to fund specific merger and acquisitions, and there might be an increased use of rights issues over placements. Both of these have been shown to more likely have a positive impact on shareholder returns. We will explore these characteristics in an upcoming publication.

During 2020 we were very involved in raisings in Australia, participating in almost all deals undertaken by companies we hold. This broad participation was based on findings on the overall positive performance (and high success rates) of raisings during the GFC, the last crisis. In most cases we bid for (and received) at least our “pro-rata” allocation which allowed us to maintain our holding in the company without dilution.

In ‘normal’ market conditions when raisings are less frequent and undertaken for different reasons we scrutinise the deal characteristics more closely with a focus on identifying deals to avoid participating in - based on the higher likelihood that these companies shares will underperform post raising.

* Source: IRESS. As at June 30^th 2021.

¹ Source: IRESS, Ownership Matters. As at June 30th 2021.

² Source: IRESS, Ownership Matters. As at June 30th 2021.

³ Note that for COVID raisings less than 12 months old the latest excess return was used.

⁴ Source: IRESS, June 30th 2021.